Protagonist Therapeutics Inc Q3 2024 Earnings EPS Loss of 0. ...
| PTGX Stock | USD 45.57 1.08 2.43% |
Slightly above 66 percent of all Protagonist Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Protagonist Therapeutics suggests that a large number of traders are confidant. Protagonist Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Protagonist Therapeutics' earnings reports, geopolitical events, and overall market trends.
Protagonist | Build AI portfolio with Protagonist Stock |
Revenue 4.7 million in license and collaboration revenue for Q3 2024, surpassing the previous years 0, driven by the Takeda Collaboration Agreement.Net Los
Read at gurufocus.com
 |
Protagonist Therapeutics Current Investor Sentiment
Comfort Level 66
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Protagonist Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Protagonist Therapeutics.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Protagonist Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Protagonist Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Protagonist Therapeutics Historical Investor Sentiment
Investor biases related to Protagonist Therapeutics' public news can be used to forecast risks associated with an investment in Protagonist. The trend in average sentiment can be used to explain how an investor holding Protagonist can time the market purely based on public headlines and social activities around Protagonist Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Protagonist Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Protagonist Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Protagonist Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Protagonist Therapeutics.
Protagonist Therapeutics Fundamental Analysis
We analyze Protagonist Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagonist Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagonist Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Protagonist Therapeutics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Protagonist Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagonist Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagonist Therapeutics could also be used in its relative valuation, which is a method of valuing Protagonist Therapeutics by comparing valuation metrics with similar companies.
Peers
Protagonist Therapeutics Related Equities
| TERN | Terns Pharmaceuticals | 9.38 | ||||
| BDTX | Black Diamond | 8.21 | ||||
| ABOS | Acumen Pharmaceuticals | 5.94 | ||||
| REPL | Replimune | 4.46 | ||||
| RLAY | Relay Therapeutics | 4.27 | ||||
| DAWN | Day One | 3.68 | ||||
| KURA | Kura Oncology | 3.65 | ||||
| VTYX | Ventyx Biosciences | 3.57 | ||||
| SNDX | Syndax Pharmaceuticals | 2.76 | ||||
| VRNA | Verona Pharma | 1.78 | ||||
| IDYA | Ideaya Biosciences | 1.46 | ||||
| RVMD | Revolution Medicines | 0.99 | ||||
| STOK | Stoke Therapeutics | 0.72 | ||||
| ARVN | Arvinas | 0.62 | ||||
| RNA | Avidity Biosciences | 0.43 | ||||
| MRUS | Merus BV | 0.48 | ||||
| AKRO | Akero Therapeutics | 1.88 | ||||
| PLRX | Pliant Therapeutics | 2.17 | ||||
| HOOK | Hookipa Pharma | 2.56 | ||||
| XFOR | X4 Pharmaceuticals | 3.31 |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.